On March 23, 2026, MIRA Pharmaceuticals reported that its drug Mira-55 showed no CNS side effects in studies, indicating potential for pain relief without opioid risks. The drug demonstrated no psychogenic effects or motor impairment at various doses, supporting plans for an IND submission for inflammatory pain.